share_log
Moomoo 24/7 ·  04/04 08:03

Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

如果獲得批准,Acumen Pharmicals與Lonza合作,涵蓋用於阿爾茨海默氏病的Sabirnetug(ACU193)的製造,用於臨床開發和商業化

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論